20/20 BioLabs Secures Exclusive CKD Prediction License with Cost-Sharing Royalty Deal
20/20 BioLabs secured an exclusive U.S. license to integrate ROKIT Healthcare’s chronic kidney disease prediction algorithm into its OneTest Longevity platform. ROKIT will reimburse one-third of agreed sales and marketing expenses in return for royalties and possible exclusive Asian commercialization rights.
1. Exclusive License and Cost-Sharing Terms
20/20 BioLabs has entered an exclusive U.S. technology license with ROKIT Healthcare to integrate its proprietary CKD prediction algorithm into the OneTest Longevity platform. Under the agreement, ROKIT will reimburse one-third of mutually agreed sales and marketing expenses in exchange for a running royalty on net sales.
2. Enhanced Disease Risk Platform
The integration adds chronic kidney disease risk assessment to existing inflammatory biomarker tracking in OneTest Longevity, targeting a U.S. patient base exceeding 35 million individuals with CKD. This enhancement aims to deliver earlier risk insights and personalized decision-support for healthcare providers and patients.
3. Market Expansion and Competitive Positioning
The agreement opens negotiations for exclusive commercialization rights of the combined platform in Korea and potentially other East Asian markets. Executives anticipate that the partnership will strengthen 20/20 BioLabs’ competitive position within the longevity analytics sector and drive broader adoption of its diagnostics.